Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome

Children with Down syndrome (DS) have a greater risk for developing both acute lymphoblastic leukaemia (ALL) and significant adverse effects of chemotherapy. We investigated their outcome with, and tolerance of, treatment protocols for relapsed ALL optimized in the paediatric population without DS....

Full description

Saved in:
Bibliographic Details
Main Authors: Meyr, Franziska (Author) , Escherich, Gabriele (Author) , Mann, Georg (Author) , Klingebiel, Thomas (Author) , Kulozik, Andreas (Author) , Rossig, Claudia (Author) , Schrappe, Martin (Author) , Henze, Günter (Author) , Stackelberg, Arend von (Author) , Hitzler, Johann (Author)
Format: Article (Journal)
Language:English
Published: 18 April 2013
In: British journal of haematology
Year: 2013, Volume: 162, Issue: 1, Pages: 98-106
ISSN:1365-2141
DOI:https://doi.org/10.1111/bjh.12348
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1111/bjh.12348
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.12348
Get full text
Author Notes:Franziska Meyr, Gabriele Escherich, Georg Mann, Thomas Klingebiel, Andreas Kulozik, Claudia Rossig, Martin Schrappe, Günter Henze, Arend von Stackelberg and Johann Hitzler

MARC

LEADER 00000caa a2200000 c 4500
001 1758317272
003 DE-627
005 20220819212752.0
007 cr uuu---uuuuu
008 210521s2013 xx |||||o 00| ||eng c
024 7 |a 10.1111/bjh.12348  |2 doi 
035 |a (DE-627)1758317272 
035 |a (DE-599)KXP1758317272 
035 |a (OCoLC)1341413770 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Meyr, Franziska  |e VerfasserIn  |0 (DE-588)1234997150  |0 (DE-627)1760010219  |4 aut 
245 1 0 |a Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome  |c Franziska Meyr, Gabriele Escherich, Georg Mann, Thomas Klingebiel, Andreas Kulozik, Claudia Rossig, Martin Schrappe, Günter Henze, Arend von Stackelberg and Johann Hitzler 
264 1 |c 18 April 2013 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 21.05.2021 
520 |a Children with Down syndrome (DS) have a greater risk for developing both acute lymphoblastic leukaemia (ALL) and significant adverse effects of chemotherapy. We investigated their outcome with, and tolerance of, treatment protocols for relapsed ALL optimized in the paediatric population without DS. Probability of survival and causes of treatment failure were determined for 49 children with DS and a matched cohort of 98 children without DS among 2160 children treated for relapsed ALL in clinical trials conducted by the Berlin-Frankfurt-Münster ALL Relapse Study Group between 1983 and 2012. Despite more favourable ALL relapse characteristics, children with DS experienced lower event-free (EFS) and overall survival (OS) than the control group without DS (EFS 17 ± 08% vs. non-DS 41 ± 06%, P = 0·006; OS 17 ± 09% vs. non-DS 51 ± 06%, P < 0·001). Children with DS developed more frequently fatal complications of treatment (34 ± 07% vs. non-DS 10 ± 04%, P < 0·001). During the last decade, EFS and OS were no longer significantly different in children with and without DS (EFS 31 ± 09% vs. 36 ± 09%, P = 0·399; OS 31 ± 12% vs. 53 ± 09%, P = 0·151). DS proved an independent prognostic factor of outcome after ALL relapse. Induction deaths and treatment-related mortality but not subsequent relapse were the main barrier to successful outcomes of relapse therapy in children with DS. 
650 4 |a acute lymphoblastic leukaemia 
650 4 |a Down syndrome 
650 4 |a outcomes 
650 4 |a relapse 
650 4 |a treatment 
700 1 |a Escherich, Gabriele  |e VerfasserIn  |4 aut 
700 1 |a Mann, Georg  |e VerfasserIn  |4 aut 
700 1 |a Klingebiel, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Kulozik, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1025736567  |0 (DE-627)723892032  |0 (DE-576)167091638  |4 aut 
700 1 |a Rossig, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Schrappe, Martin  |e VerfasserIn  |4 aut 
700 1 |a Henze, Günter  |e VerfasserIn  |4 aut 
700 1 |a Stackelberg, Arend von  |e VerfasserIn  |4 aut 
700 1 |a Hitzler, Johann  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t British journal of haematology  |d Oxford [u.a.] : Wiley-Blackwell, 1955  |g 162(2013), 1, Seite 98-106  |h Online-Ressource  |w (DE-627)269758941  |w (DE-600)1475751-5  |w (DE-576)09113997X  |x 1365-2141  |7 nnas  |a Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome 
773 1 8 |g volume:162  |g year:2013  |g number:1  |g pages:98-106  |g extent:9  |a Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome 
856 4 0 |u https://doi.org/https://doi.org/10.1111/bjh.12348  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.12348  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210521 
993 |a Article 
994 |a 2013 
998 |g 1025736567  |a Kulozik, Andreas  |m 1025736567:Kulozik, Andreas  |d 910000  |d 910500  |e 910000PK1025736567  |e 910500PK1025736567  |k 0/910000/  |k 1/910000/910500/  |p 5 
999 |a KXP-PPN1758317272  |e 3930073897 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"title":[{"title_sort":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology","title":"British journal of haematology"}],"corporate":[{"display":"British Society for Haematology","role":"isb"},{"display":"European Hematology Association","role":"isb"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"origin":[{"dateIssuedKey":"1955","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1955-"}],"note":["Gesehen am 08.05.08"],"part":{"volume":"162","text":"162(2013), 1, Seite 98-106","year":"2013","pages":"98-106","extent":"9","issue":"1"},"id":{"eki":["269758941"],"doi":["10.1111/(ISSN)1365-2141"],"issn":["1365-2141"],"zdb":["1475751-5"]},"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"language":["eng"],"disp":"Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndromeBritish journal of haematology","recId":"269758941","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1955 -"]}],"note":["Gesehen am 21.05.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1111/bjh.12348"],"eki":["1758317272"]},"physDesc":[{"extent":"9 S."}],"language":["eng"],"title":[{"title_sort":"Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome","title":"Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome"}],"recId":"1758317272","name":{"displayForm":["Franziska Meyr, Gabriele Escherich, Georg Mann, Thomas Klingebiel, Andreas Kulozik, Claudia Rossig, Martin Schrappe, Günter Henze, Arend von Stackelberg and Johann Hitzler"]},"origin":[{"dateIssuedDisp":"18 April 2013","dateIssuedKey":"2013"}],"person":[{"display":"Meyr, Franziska","given":"Franziska","family":"Meyr","role":"aut"},{"display":"Escherich, Gabriele","given":"Gabriele","family":"Escherich","role":"aut"},{"role":"aut","family":"Mann","given":"Georg","display":"Mann, Georg"},{"family":"Klingebiel","display":"Klingebiel, Thomas","given":"Thomas","role":"aut"},{"role":"aut","given":"Andreas","display":"Kulozik, Andreas","family":"Kulozik"},{"display":"Rossig, Claudia","given":"Claudia","family":"Rossig","role":"aut"},{"given":"Martin","display":"Schrappe, Martin","family":"Schrappe","role":"aut"},{"role":"aut","family":"Henze","given":"Günter","display":"Henze, Günter"},{"family":"Stackelberg","display":"Stackelberg, Arend von","given":"Arend von","role":"aut"},{"family":"Hitzler","given":"Johann","display":"Hitzler, Johann","role":"aut"}]} 
SRT |a MEYRFRANZIOUTCOMESOF1820